Navigation Links
ATS Medical Announces First Commercial Implants of the ATS 3f Aortic Bioprosthesis in the United States

MINNEAPOLIS, Nov. 24 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that the first three commercial implants of the ATS 3f(R) Aortic Bioprosthesis were completed by Dr. Allan Stewart, Director, Aortic Surgery Program at Columbia University Medical Center in New York ( on November 17 and 18, 2008.


The ATS 3f Aortic Bioprosthesis is the Company's first entry into the $400-plus million U.S. tissue valve market. Based on the precept that 'Form Follows Function', the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve.

"The ATS 3f Aortic Bioprosthesis is the only tissue valve that preserves the sinuses and restores native valve stress distribution and physiologic flow to the entire aortic root," commented Dr. Stewart. "All three patients achieved postoperative aortic function that is nearly indistinguishable from a healthy native aortic valve. All three patients have been discharged with an excellent prognosis and remarkably low pressure gradients of 4, 2, and 0 mm Hg."

"The commercial launch of our first tissue valve in the U.S. is an important milestone for ATS Medical," added Mr. Dale, President and Chief Executive Officer of ATS Medical. "The tissue valve market presents the largest market opportunity of our current products and will importantly provide ATS Medical the leverage it needs to sustain high growth and enhanced profitability in the future. We are grateful to Dr. Stewart for his commitment to science and excellent patient care."

The tubular design of the ATS 3f Aortic Bioprosthesis maintains the continuity of the annulus and the sino-tubular junction. No other valve mimics the native valve in this manner. By maintaining this continuity, the ATS 3f Aortic Bioprosthesis preserves the aortic sinuses and restores native valve stress distribution and physiologic blood flow. This elegant design provides surgeons and patients with a potentially more durable solution to aortic valve replacement.

With more than six years of clinical experience confirming excellent safety and efficacy, the demonstrated clinical benefit and recent FDA approval of the ATS 3f Aortic Bioprosthesis are creating excitement and product demand among U.S. surgeons. The Company is currently conducting a limited launch of the ATS 3f Aortic Bioprosthesis at a few select institutions in the fourth quarter of 2008 and plans a broader launch of the valve during the first quarter of 2009.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 160,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the outcome of pending litigation matters, the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.

SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Minnesota Nurses Support SEIU Workers at Regina Medical Center, Hastings
2. When Is Screening for Renal Artery Stenosis Medically Necessary?
3. Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame.
4. Symmetry Medical to Present at 20th Annual Piper Jaffray Healthcare Conference
5. Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing
6. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
7. ReachMD Announces New Strategic Partnership with American Medical Directors Association
8. Photos: Nevadas Saint Marys Regional Medical Center Raises $1.3 Million During Centennial Soiree
9. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
10. Video: Intel Announces its First Home Medical Device in the United Kingdom to Better Connect Clinicians With Patients
11. Medical Technology to be Highlighted at World's Largest Simulation Exhibition
Post Your Comments:
(Date:11/24/2015)... VA (PRWEB) , ... November 24, 2015 , ... ... people across the United States to support their local poison centers through donations ... designated as #GivingTuesday: calls it “a day that inspires people to collaborate ...
(Date:11/24/2015)... ... 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance ... some of the staff members at their recovery center. The videos highlight some of ... some of the things that make their recovery program so unique. , “Making the ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... 2015 , ... Dr. Rodney E. Willey , has answered a new calling – to ... Disorders, provides treatment for snoring and sleep apnea through oral appliance therapy. ... Sleep Disorders in the US, one of four in the Illinois area. , Dr. ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015 F1000Workspace - a ... since it was launched just six months ago. --> ... authoring platform for scientists - since it was launched just ... been loaded on to F1000Workspace - a research ... it was launched just six months ago. ...
(Date:11/24/2015)... Nov. 24, 2015 iRhythm Technologies, Inc. , a ... today announced that it will participate in the 27th Annual Piper ... New York, NY . Kevin King , ... December 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: